Related Experiment Video
Updated: Jun 21, 2026
07:15
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Lithium-induced membranous glomerulonephropathy in a pediatric patient
Gunjeet K Kala1, Muniza Mogri, Edit Weber-Shrikant
1Women and Children's Hospital of Buffalo, New York 14222, USA. gkala1@hotmail.com
Pediatric Nephrology (Berlin, Germany)
|July 8, 2009
Summary
Lithium can rarely cause kidney damage in children. This case report details a pediatric patient who developed membranous glomerulonephropathy due to long-term lithium use, with symptoms resolving after treatment cessation.
Area of Science:
- Nephrology
- Pediatric Nephrology
- Toxicology
Background:
- Lithium is a common mood stabilizer, but its nephrotoxic potential, particularly in pediatric populations, is not well-established.
- Membranous glomerulonephropathy (MGN) is a significant cause of nephrotic syndrome in children and adults.
- Alkali metals have been anecdotally linked to MGN, but lithium's specific role remains unclear.
Observation:
- A 13-year-old patient exhibited renal insufficiency and laboratory abnormalities following extended lithium therapy.
- Kidney biopsy confirmed the presence of membranous glomerulonephropathy.
Findings:
- This case represents the first documented instance of lithium-induced glomerulonephropathy in a pediatric patient.
- Discontinuation of lithium treatment led to the complete resolution of the patient's renal symptoms and laboratory findings.
Implications:
- This report highlights the importance of monitoring renal function in pediatric patients on long-term lithium treatment.
- It suggests lithium as a potential causative agent for membranous glomerulonephropathy in children.
- Further research is warranted to elucidate the mechanisms of lithium nephrotoxicity and its association with MGN.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...